NBSE - Shares of NeuBase Therapeutics Inc. (NBSE) Fall Below Previous 52-Week Low
NeuBase Therapeutics Inc. (NASDAQ:NBSE) traded today at a new 52-week low of $5.76. So far today approximately 188,000 shares have been exchanged, as compared to an average 30-day volume of 216,000 shares.
NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
In the past 52 weeks, NeuBase Therapeutics Inc. share prices are bracketed by a current low of $5.76 and a high of $12.89 and is now at $5.87.
NeuBase Therapeutics Inc. has overhead space with shares priced $5.87, or 17.4% below the average consensus analyst price target of $7.11.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer